Application of Amniotic Tissue Matrix to Surgically Excised Hidradenitis Suppurativa Wounds: A Retrospective Review

Background: Hidradenitis suppurativa is a painful and disfiguring disease, which requires surgical management in severe cases. Improvements in management are necessary to decrease disease morbidity and improve outcomes. Aim: To determine the efficacy of applying amniotic tissue matrix to surgically-excised hidradenitis suppurativa wounds. Materials & Methods: A 5-year retrospective chart review of patients who underwent surgical treatment of perineal, perianal, and inguinal hidradenitis suppurativa at the University of Miami Hospital was completed. The study group consisted of 5 patients who had amniotic tissue matrix applied to their surgical wounds postoperatively. The control group, 18 patients, did not receive the amniotic tissue matrix application. Results: The average disease surface area in the study group was larger at 1278 ± 723 cm2 compared to 700 ± 555 cm2 for the control group. Duration of intensive care unit admission in the study group was shorter at 4.2 ± 4.3 days compared to 6.7 ± 8.8 days for the control group. Duration of inpatient admission was longer in the study group, 28.2 ± 12.4 days, compared to 24.6 ± 11.9 days for the control group. Postoperative hypergranulation tissue occurred more frequently in the control group (52.6%) than in the study group (20%). Conclusion: While further evaluation in a larger cohort of patients is necessary, application of amniotic tissue matrix to surgically-excised hidradenitis wounds appears to offer an adjunctive improvement to the treatment of hidradenitis.